BioSpace News Archive

ReceivedIMPDApproval to CommenceEnrollment in France for PivotalPhase 3Studyof Galinpepimut-S in Acute Myeloid Leukemia Patients

Transplant Genomics, Inc. (“TGI”) a member of Eurofins Transplant Diagnostics, is excited to introduce TruGraf Liver, the only non-invasive blood-based test to assist in lowering immunosuppression in liver transplant patients, at The Liver Meeting Digital Experience (“The Liver Meeting”).

Medtronic plc, the global leader in medical technology, announced that it has been recognized as one of the world’s leading companies for sustainability with its inclusion in the Dow Jones Sustainability North America Index.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the publication of positive results from a study of antiviral activity of FDA approved drugs in a peer-reviewed article in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

ExeGi Pharma LLC, a company focused on developing live biotherapeutic (“LBP”) drugs and probiotics, announced today that its biologic drug candidate, EXE-346, has received an orphan drug designation from the U.S. Food and Drug Administration (FDA) for the prevention of disease relapse in pouchitis.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced positive interim clinical data from AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company’s second-generation investigational RNA interference (RNAi) therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim data from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for the treatment of hypertension.

Enzolytics Inc. oday shared the following update provided by ENZC’s Merger target BioClonetics Immunotherapeutics, Inc. (“BCLS” or “BioClonetics”), resulting from the application of proceeds from the initial funding received on October 26, 2020

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at 1:45 pm ET.

Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the pricing of its previously announced underwritten public offering